Elizabeth Claire Dees

Author

University of North Carolina at Chapel Hill ORCID

Also Known As

Abramson, Richard G, Dees, E. C., Dees, Elizabeth Claire, E C Dees, E Claire Dees, E. C. Dees, E. Claire Dees, E. Dees, E.C. Dees, Elizabeth C Dees

406

Publications

15.4K

Citations

H-Index

111

Concepts

All Affiliations

University of North Carolina at Chapel Hill UNC Lineberger Comprehensive Cancer Center The University of Texas MD Anderson Cancer Center Dana-Farber Cancer Institute Sarah Cannon

About

Elizabeth Claire Dees is an author at University of North Carolina at Chapel Hill specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	26	51	3.5K
2	Health Sciences	12	12	834
3	Natural Sciences	3	3	1.5K
4	Engineering	2	2	84
5	Nursing	1	1	61

Elizabeth Claire Dees

103

Publications

15K

Citations

H-Index

Page 1

	Year	Citations
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer Joseph A. Sparano, Robert J. Gray, Della Makower, New England Journal of Medicine	2018	2.3K
The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes Lisa A. Carey, Elizabeth Claire Dees, Lynda Sawyer, Clinical Cancer Research	2007	2.1K
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study Rita Nanda, Laura Q.M. Chow, Elizabeth Claire Dees, Journal of Clinical Oncology	2016	1.4K
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer Joseph A. Sparano, Robert J. Gray, Della Makower, New England Journal of Medicine	2015	1.4K
The product of the H19 gene may function as an RNA. Camilynn I. Brannan, Elizabeth Claire Dees, Robert S. Ingram, Molecular and Cellular Biology GeneticsMolecular BiologyMolecular GeneticsEpigeneticsH19 Gene	1990	1.1K
Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas Howard A. Burris, Herbert I. Hurwitz, Elizabeth Claire Dees, Journal of Clinical Oncology	2005	620
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer Joseph A. Sparano, Robert J. Gray, Peter M. Ravdin, New England Journal of Medicine	2019	532
The proteasome as a target for cancer therapy. Peter M. Voorhees, Elizabeth Claire Dees, Bert H. O’Neil, PubMed Cancer TherapyProteasome InhibitorsChemoprevention StrategyProteasomeProteasome Impact	2003	401
The Product of the <i>H19</i> Gene May Function as an RNA Camilynn I. Brannan, Elizabeth Claire Dees, Robert S. Ingram, Molecular and Cellular Biology GeneticsRna SplicingMolecular BiologyMolecular GeneticsGene Transcription	1990	382
Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies Robert Z. Orlowski, Peter M. Voorhees, Reynaldo Garcia, Blood	2004	319

Page 1